Clinical Trial Update: Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema [Phase 2]

View source ↗

Summary

Phase 2 trial updating efficacy and safety of BCX7353 to prevent angioedema attacks in hereditary angioedema (HAE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• BCX7353

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema (HAE) | Phase 2 | Status: COMPLETED | Results posted: 2021-03-04